Inovio Pharmaceuticals (INO) Corporate presentation summary

Strategic focus and platform overview

• Developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, with a lead program targeting Recurrent Respiratory Papillomatosis (RRP).

• Proprietary CELLECTRA delivery device enhances DNA medicine uptake and supports commercial-scale manufacturing.

• Platform enables tailored in vivo protein expression, inducing cytotoxic T cells and monoclonal antibodies for disease treatment and prevention.

• DNA medicines are versatile, well-tolerated, allow re-dosing, and do not require frozen storage.

• $58.5M in cash and equivalents as of 12/31/25, supporting ongoing development.

Clinical pipeline and lead candidate progress

• Deep pipeline includes late-stage and next-generation candidates for HPV, immuno-oncology, and infectious diseases.

• INO-3107 for RRP has BLA accepted by FDA under accelerated approval, with PDUFA date set for October 30, 2026.

• INO-3107 demonstrated significant reduction in surgeries for RRP patients, with ORR improving from 72% at 1 year to 86% at 2 years.

• Immunology data show antigen-specific T cell responses correlating with clinical benefit in RRP.

• Market research supports strong efficacy, tolerability, and simplicity for INO-3107, with launch preparations underway.

Expansion and partnerships

• Advancing programs through collaborations, including Akeso and Dana-Farber for glioblastoma and Coherus for HPV-related throat cancer.

• INO-3112 and LOQTORZI combination targets HPV-related oropharyngeal cancer, with Phase 3 trial planned.

• INO-5412 with cadonilimab for glioblastoma to be evaluated in Phase 2 INSIGHT trial.

• DMAb technology enables in vivo monoclonal antibody production, with durable expression and favorable safety in Phase 1.

• DPROT platform aims to address rare diseases with long-term protein expression, showing promising preclinical results in hemophilia A.